169 related articles for article (PubMed ID: 24257318)
1. Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin.
Gold DV; Newsome G; Liu D; Goldenberg DM
Mol Cancer; 2013 Nov; 12(1):143. PubMed ID: 24257318
[TBL] [Abstract][Full Text] [Related]
2. Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: a promising biomarker and therapeutic target for pancreatic cancer.
Liu D; Chang CH; Gold DV; Goldenberg DM
Oncotarget; 2015 Feb; 6(6):4274-85. PubMed ID: 25595893
[TBL] [Abstract][Full Text] [Related]
3. Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry.
Shi C; Merchant N; Newsome G; Goldenberg DM; Gold DV
Arch Pathol Lab Med; 2014 Feb; 138(2):220-8. PubMed ID: 24476519
[TBL] [Abstract][Full Text] [Related]
4. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.
Gold DV; Karanjawala Z; Modrak DE; Goldenberg DM; Hruban RH
Clin Cancer Res; 2007 Dec; 13(24):7380-7. PubMed ID: 18094420
[TBL] [Abstract][Full Text] [Related]
5. PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma.
Gold DV; Gaedcke J; Ghadimi BM; Goggins M; Hruban RH; Liu M; Newsome G; Goldenberg DM
Cancer; 2013 Feb; 119(3):522-8. PubMed ID: 22898932
[TBL] [Abstract][Full Text] [Related]
6. Predictive Value of MUC5AC Signature in Pancreatic Ductal Adenocarcinoma: A Hypothesis Based on Preclinical Evidence.
Manne A; Kasi A; Esnakula AK; Paluri RK
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175794
[TBL] [Abstract][Full Text] [Related]
7. Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin.
Gold DV; Lew K; Maliniak R; Hernandez M; Cardillo T
Int J Cancer; 1994 Apr; 57(2):204-10. PubMed ID: 7512537
[TBL] [Abstract][Full Text] [Related]
8. Semiquantitative immunohistochemistry for mucin (MUC1, MUC2, MUC3, MUC4, MUC5AC, and MUC6) profiling of pancreatic ductal cell adenocarcinoma improves diagnostic and prognostic performance.
Sierzega M; Młynarski D; Tomaszewska R; Kulig J
Histopathology; 2016 Oct; 69(4):582-91. PubMed ID: 27165582
[TBL] [Abstract][Full Text] [Related]
9. The role of PAM4 in the management of pancreatic cancer: diagnosis, radioimmunodetection, and radioimmunotherapy.
Han S; Jin G; Wang L; Li M; He C; Guo X; Zhu Q
J Immunol Res; 2014; 2014():268479. PubMed ID: 24818166
[TBL] [Abstract][Full Text] [Related]
10. A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study.
Kaur S; Smith LM; Patel A; Menning M; Watley DC; Malik SS; Krishn SR; Mallya K; Aithal A; Sasson AR; Johansson SL; Jain M; Singh S; Guha S; Are C; Raimondo M; Hollingsworth MA; Brand RE; Batra SK
Am J Gastroenterol; 2017 Jan; 112(1):172-183. PubMed ID: 27845339
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models.
Patel SP; Bristol A; Saric O; Wang XP; Dubeykovskiy A; Arlen PM; Morse MA
Cancer Immunol Immunother; 2013 Jun; 62(6):1011-9. PubMed ID: 23591984
[TBL] [Abstract][Full Text] [Related]
12. Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology.
Han L; Pansare V; Al-Abbadi M; Husain M; Feng J
Diagn Cytopathol; 2010 May; 38(5):333-6. PubMed ID: 19856421
[TBL] [Abstract][Full Text] [Related]
13. Identification of HLA-A*0201- and A*2402-restricted epitopes of mucin 5AC expressed in advanced pancreatic cancer.
Yamazoe S; Tanaka H; Iwauchi T; Yoshii M; Ito G; Amano R; Yamada N; Sawada T; Ohira M; Hirakawa K
Pancreas; 2011 Aug; 40(6):896-904. PubMed ID: 21697763
[TBL] [Abstract][Full Text] [Related]
14. Analysis of sialyl-Lewis x on MUC5AC and MUC1 mucins in pancreatic cancer tissues.
Balmaña M; Duran A; Gomes C; Llop E; López-Martos R; Ortiz MR; Barrabés S; Reis CA; Peracaula R
Int J Biol Macromol; 2018 Jun; 112():33-45. PubMed ID: 29408556
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of mucins (MUC1, MUC2 and MUC5AC) expression profile in endoscopic ultrasound-guided fine-needle aspiration specimens of the pancreas.
Wang Y; Gao J; Li Z; Jin Z; Gong Y; Man X
Int J Cancer; 2007 Dec; 121(12):2716-22. PubMed ID: 17708554
[TBL] [Abstract][Full Text] [Related]
16. Understanding the Clinical Impact of MUC5AC Expression on Pancreatic Ductal Adenocarcinoma.
Manne A; Esnakula A; Abushahin L; Tsung A
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205412
[TBL] [Abstract][Full Text] [Related]
17. Targeting of xenografted pancreatic cancer with a new monoclonal antibody, PAM4.
Gold DV; Alisauskas R; Sharkey RM
Cancer Res; 1995 Mar; 55(5):1105-10. PubMed ID: 7866995
[TBL] [Abstract][Full Text] [Related]
18. Detection of early-stage pancreatic adenocarcinoma.
Gold DV; Goggins M; Modrak DE; Newsome G; Liu M; Shi C; Hruban RH; Goldenberg DM
Cancer Epidemiol Biomarkers Prev; 2010 Nov; 19(11):2786-94. PubMed ID: 20810605
[TBL] [Abstract][Full Text] [Related]
19. Mucin gene expression in intraductal papillary-mucinous pancreatic tumours and related lesions.
Terris B; Dubois S; Buisine MP; Sauvanet A; Ruszniewski P; Aubert JP; Porchet N; Couvelard A; Degott C; Fléjou JF
J Pathol; 2002 Aug; 197(5):632-7. PubMed ID: 12210083
[TBL] [Abstract][Full Text] [Related]
20. Mapping of the 45M1 epitope to the C-terminal cysteine-rich part of the human MUC5AC mucin.
Lidell ME; Bara J; Hansson GC
FEBS J; 2008 Feb; 275(3):481-9. PubMed ID: 18167142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
